Koninklijke Philips N.V. Q3 2026 Earnings Recap

Philips shares rose 11.7% after Q3, with the strongest signals coming from 8% order intake growth and a 70-basis-point margin increase to 13%, which was ahead of management’s expectations. Full-year outlook was reiterated; sales growth was approximately 3%, with Diagnosis & Treatment broadly flat and Connected Care orders declining mid-single digit.

Key Takeaways

• Equipment order intake grew 8%, including nearly 20% growth in Diagnosis & Treatment; the equipment order book increased sequentially and year on year.
• Comparable sales grew approximately 3%. Personal Health grew 8%, while Diagnosis & Treatment was broadly flat amid ultrasound shipment phasing and lower China sales.
• Adjusted EBITA margin increased 70 basis points to 13%; free cash flow was an inflow of EUR 384 million.
• Connected Care order intake declined mid-single digit against a prior-year quarter that grew more than 20%; some major agreements shifted into Q4 amid longer negotiation and contracting cycles.
• Philips recorded a EUR 288 million provision related to the agreement in principle with the U.S. Department of Justice over Respironics. Management reiterated its full-year outlook.